Prostate Cancer : Episode 7

Video

Episode 6 - Treatment Response Rates in Step Therapy

During this segment, David Quinn, MD, and Michael Kolodziej, MD, discuss the challenges clinicians face when developing a drug-sequencing plan for patients with castration-resistant prostate cancer.

Dr Quinn explains that because not all patients respond to the same types of therapy, there is a need for data that reveals the appropriateness of agents suggested in step therapy plans.

To address this challenge, he suggests that new clinical trials test comparative effectiveness, which he believes can help determine response rates for specific groups of patients.

Dr Kolodziej argues that receiving this data will take too long, and suggests receiving aid from professional services that can structure current data into an actionable format. He explains that this may help provide quick answers about step therapy and can improve the clinician’s decision-making process.


Related Videos
Fran Gregory, PharmD, MBA, sitting for a video interview
Casey Koch, PharmD, sitting for a video interview
H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview
Dr Raymond Osarogiagbon
Richard J. Nowak, MD, MS, Yale School of Medicine
Naim Alkhouri, MD
Jaime Almandoz, MD, MBA
Martin Edelman, MD
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Pierluigi Porcu, MD
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo